CRISPR Makes Prostate Cancer Vulnerable to Immunotherapy
Prostate cancer tumors can now be made vulnerable to immunotherapy using an experimental RNA-targeting technology developed by researchers, overcoming a major barrier that has historically left these malignancies “immune cold” and resistant to treatment. Why Prostate Tumors Resist Immunotherapy Most prostate tumors attract very few T cells, meaning the microscopic environment lacks enough infiltrating immune … Read more